493 related articles for article (PubMed ID: 9819135)
1. Molecular aspects of Huntington's disease.
Walling HW; Baldassare JJ; Westfall TC
J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
3. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.
Bao J; Sharp AH; Wagster MV; Becher M; Schilling G; Ross CA; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 1996 May; 93(10):5037-42. PubMed ID: 8643525
[TBL] [Abstract][Full Text] [Related]
4. [Huntington disease. A review].
Bonilla E
Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
[TBL] [Abstract][Full Text] [Related]
5. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
6. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
7. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
Li SH; Li XJ
Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
[TBL] [Abstract][Full Text] [Related]
8. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.
Jana NR; Tanaka M; Wang Gh; Nukina N
Hum Mol Genet; 2000 Aug; 9(13):2009-18. PubMed ID: 10942430
[TBL] [Abstract][Full Text] [Related]
9. Towards a transgenic model of Huntington's disease in a non-human primate.
Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
[TBL] [Abstract][Full Text] [Related]
10. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
[TBL] [Abstract][Full Text] [Related]
11. Polyglutamine pathogenesis.
Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
[TBL] [Abstract][Full Text] [Related]
12. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein.
Omi K; Hachiya NS; Tanaka M; Tokunaga K; Kaneko K
Neurosci Lett; 2008 Jan; 431(1):45-50. PubMed ID: 18078716
[TBL] [Abstract][Full Text] [Related]
13. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
[TBL] [Abstract][Full Text] [Related]
14. The early cellular pathology of Huntington's disease.
Li XJ
Mol Neurobiol; 1999; 20(2-3):111-24. PubMed ID: 10966117
[TBL] [Abstract][Full Text] [Related]
15. [Huntington's disease: intracellular signaling pathways and neuronal death].
Humbert S; Saudou F
J Soc Biol; 2005; 199(3):247-51. PubMed ID: 16471265
[TBL] [Abstract][Full Text] [Related]
16. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R; Atwal RS; Burtnik A
Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
[TBL] [Abstract][Full Text] [Related]
17. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.
Nucifora FC; Sasaki M; Peters MF; Huang H; Cooper JK; Yamada M; Takahashi H; Tsuji S; Troncoso J; Dawson VL; Dawson TM; Ross CA
Science; 2001 Mar; 291(5512):2423-8. PubMed ID: 11264541
[TBL] [Abstract][Full Text] [Related]
18. Huntington's disease: from pathology and genetics to potential therapies.
Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
[TBL] [Abstract][Full Text] [Related]
19. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
20. Genetics and neuropathology of Huntington's disease.
Reiner A; Dragatsis I; Dietrich P
Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
